Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. The Company's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like receptors (TLRs). In addition to its TLR programs, it is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

Employee Rating

4.3More
TypePublic
HQCambridge, US
Founded1989
Size (employees)62 (est)
Websiteiderapharma.com
Idera Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Idera Pharmaceuticals

Sudhir Agrawal

Sudhir Agrawal

Chief Executive Officer and President, Board of Directors
Louis J. Arcudi

Louis J. Arcudi

Senior Vice President of Operations, Chief Financial Officer, Treasurer, and Secretary
Robert D. Arbeit

Robert D. Arbeit

Vice President, Clinical Development
Timothy M. Sullivan

Timothy M. Sullivan

Vice President, Development Programs and Alliance Management
Show more

Idera Pharmaceuticals Office Locations

Idera Pharmaceuticals has offices in Cambridge and Exton
Cambridge, US (HQ)
167 Sidney Street
Exton, US
505 Eagleview Blvd, Suite 212
Show all (2)
Report incorrect company information

Idera Pharmaceuticals Financials and Metrics

Idera Pharmaceuticals Revenue

Idera Pharmaceuticals's revenue was reported to be $249 k in FY, 2015 which is a 241.1% increase from the previous period.
USD

Net income (Q2, 2018)

(36.1m)

EBIT (Q2, 2018)

(36.6m)

Market capitalization (3-Aug-2018)

2.3m

Closing stock price (3-Aug-2018)

5.5

Cash (30-Jun-2018)

94.0m
Idera Pharmaceuticals's current market capitalization is $2.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

47.0k73.0k249.0k

Revenue growth, %

55%241%

General and administrative expense

7.7m15.4m15.1m16.7m

R&D expense

10.5m33.7m39.8m50.7m
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

2.2m2.0m2.9m3.8m4.0m3.9m3.8m3.9m4.1m3.9m3.9m7.0m12.6m

R&D expense

2.5m6.9m6.7m9.0m7.5m9.3m10.1m9.4m11.5m17.9m10.9m13.6m24.4m

Operating expense total

4.7m9.0m9.6m12.8m11.5m13.2m13.9m13.3m15.6m21.8m14.8m20.5m37.0m

EBIT

(4.7m)(9.0m)(9.5m)(12.8m)(11.5m)(12.9m)(13.6m)(13.0m)(15.2m)(21.6m)(14.7m)(20.3m)(36.6m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

26.3m20.0m26.6m80.7m112.6m

Accounts Receivable

Inventories

874.0k1.2m3.1m2.0m

Current Assets

30.3m42.4m63.2m111.0m116.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.2m)(38.6m)(48.6m)(38.4m)

Depreciation and Amortization

137.0k206.0k488.0k656.0k

Inventories

(676.0k)(329.0k)(1.9m)1.1m
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(12.1m)(9.0m)(26.7m)(12.7m)(11.4m)(12.8m)(13.5m)(12.9m)(15.1m)

Depreciation and Amortization

106.0k31.0k135.0k

Accounts Payable

2.8m881.0k958.0k629.0k344.0k1.4m529.0k

Cash From Operating Activities

(12.7m)(7.6m)(21.8m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Idera Pharmaceuticals News and Updates

Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

EXTON, Pa., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) at the Westin St. Francis Ho…

Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

- 32.4% of patients evaluable for efficacy achieved partial response or better; 76.5% of patients achieved disease control -   - Tumor shrinkage observed in both injected and uninjected lesions, indicating an abscopal effect -

Idera Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

–  Company to Provide ILLUMINATE 204 Data Update in the First Half of December 2018 – –  Cash runway into first quarter of 2020 –

Idera Pharmaceuticals Announces Appointment of Howard Pien to its Board of Directors

EXTON, Pa., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that Howard Pien joined its Board of …

Idera Pharmaceuticals Announces Corporate Organizational Changes

- Bryant D. Lim appointed as General Counsel and Secretary of the Board of Directors -
Show more
Report incorrect company information

Idera Pharmaceuticals Blogs

Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors

EXTON, Pa. , Dec. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Carol A. Schafer joined its Board of Directors, effective December 18 , 2018.  Ms. Schafer is a seasoned financial professional with more than 25 years of experience in investment banking

Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018

Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018 Content Import Wed, 12/12/2018 - 16:03 Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018 Dec 12, 2018 This releas…

Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment at the 2018 European Society for Medical Oncology (ES

- Key findings presented in poster discussion demonstrate clear abscopal effect of intratumoral tilsotolimod - - Data demonstrate contribution of tilsotolimod to overcome resistance to ipilimumab in patients with low HLA-ABC expression - - Company plans to provide additional clinical safety and

Bryant D. Lim

Bryant D. Lim Michael.Fuccio… Thu, 10/04/2018 - 14:48 Bryant D. Lim Senior Vice President, General Counsel, Secretary of the Board of Directors Mr. Bryant D. Lim joined Idera in September of 2018 as General Counsel and Secretary of the Board of Directors.  Pri…

Howard Pien

Howard Pien Michael.Fuccio… Thu, 10/04/2018 - 14:43 Member of the Compensation Committee Howard Pien Director Mr. Howard Pien was appointed a member of Idera’s Board of Directors in September 2018.  Mr. Pien has worked in the pharmaceutical and biotechnology indus…

Barclays – Gena Wang, Ph.D., CFA

Barclays – Gena Wang, Ph.D., CFA Michael.Fuccio… Thu, 10/04/2018 - 14:35 Gena Wang, Ph.D., CFA Barclays
Show more

Idera Pharmaceuticals Company Life and Culture

Report incorrect company information

Idera Pharmaceuticals Frequently Asked Questions

  • When was Idera Pharmaceuticals founded?

    Idera Pharmaceuticals was founded in 1989.

  • Who are Idera Pharmaceuticals key executives?

    Idera Pharmaceuticals's key executives are Sudhir Agrawal, Louis J. Arcudi and Robert D. Arbeit.

  • How many employees does Idera Pharmaceuticals have?

    Idera Pharmaceuticals has 62 employees.

  • Who are Idera Pharmaceuticals competitors?

    Competitors of Idera Pharmaceuticals include Atopix, Biothera and Hospira.

  • Where is Idera Pharmaceuticals headquarters?

    Idera Pharmaceuticals headquarters is located at 167 Sidney Street, Cambridge.

  • Where are Idera Pharmaceuticals offices?

    Idera Pharmaceuticals has offices in Cambridge and Exton.

  • How many offices does Idera Pharmaceuticals have?

    Idera Pharmaceuticals has 2 offices.